Peregrine Capital Management LLC Buys 5,759 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Peregrine Capital Management LLC lifted its position in Privia Health Group, Inc. (NASDAQ:PRVA) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 320,768 shares of the company’s stock after buying an additional 5,759 shares during the quarter. Peregrine Capital Management LLC owned about 0.27% of Privia Health Group worth $6,271,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Park Avenue Securities LLC grew its position in shares of Privia Health Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 14,697 shares of the company’s stock valued at $287,000 after acquiring an additional 532 shares during the period. Sequoia Financial Advisors LLC grew its holdings in Privia Health Group by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 26,246 shares of the company’s stock worth $478,000 after purchasing an additional 583 shares during the period. KBC Group NV increased its position in Privia Health Group by 34.6% during the third quarter. KBC Group NV now owns 3,385 shares of the company’s stock worth $62,000 after buying an additional 871 shares during the last quarter. Fifth Third Bancorp raised its stake in Privia Health Group by 38.3% in the fourth quarter. Fifth Third Bancorp now owns 5,105 shares of the company’s stock valued at $100,000 after buying an additional 1,415 shares during the period. Finally, Choreo LLC lifted its position in shares of Privia Health Group by 8.7% in the fourth quarter. Choreo LLC now owns 21,841 shares of the company’s stock valued at $425,000 after buying an additional 1,752 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PRVA has been the topic of a number of research analyst reports. Stephens restated an “overweight” rating and issued a $26.00 price target on shares of Privia Health Group in a research note on Thursday, January 2nd. Needham & Company LLC started coverage on Privia Health Group in a research note on Friday, January 10th. They issued a “buy” rating and a $25.00 price target for the company. Macquarie assumed coverage on Privia Health Group in a report on Monday, December 16th. They set an “outperform” rating and a $25.00 target price for the company. JPMorgan Chase & Co. upped their price target on shares of Privia Health Group from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, November 29th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $26.00 price objective on shares of Privia Health Group in a research note on Friday, February 14th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $24.94.

Privia Health Group Stock Down 0.8 %

Privia Health Group stock opened at $25.04 on Wednesday. The stock has a market cap of $3.00 billion, a PE ratio of 250.43, a P/E/G ratio of 3.07 and a beta of 0.87. Privia Health Group, Inc. has a 12-month low of $15.92 and a 12-month high of $25.64. The business’s 50-day moving average price is $21.76 and its two-hundred day moving average price is $20.29.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.